In September 2024, the Criminal Division of the Department of Justice (DOJ) issued a significant update to its Evaluation of Corporate Compliance Programs (ECCP) policy document, introducing detailed […]
Avoiding or Addressing USPTO Rejections for Written Description and Enablement
Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement rejections under 35 U.S.C. §112(a). The United States Patent & Trademark Office […]